Back To: Home : Featured Technology : Functional Genomic Screening

CLICK HERE FOR WHAT'S NEW IN:
 

Response Genetics nets subcontract for ALCHEMIST initiative
October 2014
SHARING OPTIONS:

LOS ANGELES—Response Genetics Inc. was recently awarded a multimillion-dollar research subcontract by Leidos Biomedical Research Inc., the operations and technical support contractor for the Frederick National Laboratory for Cancer Research, which is sponsored by the National Cancer Institute (NCI). Response Genetics will be supporting the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST), which consist of three integrated precision medicine trials being implemented by the NCI’s National Clinical Trials Network. Through ALCHEMIST, thousands of patients with resected early-stage lung cancer will be screened over five to six years to locate patients with EGFR gene mutations and ALK gene arrangement. The initiative will also aim to define the progression of early-stage lung cancer, evaluate two therapies as adjuvants and offer a public resource with the genomic characterization of participants’ tumors.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.